TROV
(NASDAQ)
1.05
+0.0416  (+3.96%)
Volume (24h): 74,405.00 Day Range: 1.01 - 1.07
Market Cap: 10.40M 52W Range: 0.7010 - 5.56
Mar-05-20 01:15PM Trovagene Announces Three New Nominees for Election to Board of DirectorsPR Newswire
Feb-27-20 09:15PM Trovagene Announces Fourth Quarter and Full-Year 2019 ResultsPR Newswire
Feb-13-20 01:00PM Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC PatientsPR Newswire
Feb-05-20 01:00PM Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers SymposiumPR Newswire
Jan-31-20 05:01PM Should You Worry About TrovaGene, Inc.'s (NASDAQ:TROV) CEO Salary Level?Simply Wall St.
Jan-29-20 01:00PM Trovagene Receives Approximately $1.45 Million From Exercise of WarrantsPR Newswire
Jan-27-20 01:00PM Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC PatientsPR Newswire
Jan-21-20 01:00PM Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers SymposiumPR Newswire
Dec-09-19 01:00PM Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASHPR Newswire
Dec-04-19 01:00PM Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)PR Newswire
Nov-14-19 01:44PM Benzinga Pro's Top 5 Stocks To Watch For Thurs., Nov. 14, 2019: NVDA, SINA, DDS, TROV, AMRNBenzinga
01:00PM Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®PR Newswire
Nov-07-19 09:20PM Trovagene Announces Third Quarter 2019 Results and HighlightsPR Newswire
Nov-06-19 02:00PM Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual MeetingPR Newswire
Oct-25-19 05:37PM Trovagene Announces $5.0 Million Private Placement Priced At-the-MarketPR Newswire
Oct-23-19 07:00PM TrovaGene (NASDAQ:TROV) Will Have To Spend Its Cash WiselySimply Wall St.
Oct-22-19 12:15PM Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal CancerPR Newswire
Oct-02-19 12:15PM Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer (TNBC)PR Newswire
Oct-01-19 04:58PM A Look At Benzinga Pro's Most-Searched Tickers For October 1, 2019Benzinga
12:15PM Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMOPR Newswire
Sep-30-19 04:05PM A Look At Benzinga Pro's Most-Searched Tickers For September 30, 2019Benzinga
12:15PM Positive Data from Trovagene Phase 1b/2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) ConferencePR Newswire
Sep-20-19 02:51PM Trovagene's Onvansertib Shows Response in Phase Ib AML StudyZacks
Sep-19-19 12:15PM Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2PR Newswire
Sep-03-19 12:15PM Trovagene to Present at the H.C. Wainwright 21st Annual Global Investment ConferencePR Newswire
Aug-26-19 03:49PM A Look At Benzinga Pro's Most-Searched Tickers For August 26, 2019Benzinga
12:00PM Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)PR Newswire
Aug-25-19 07:06PM The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day WeekendBenzinga
Aug-21-19 08:33PM TrovaGene Shares Volatile Ahead of Oncology PresentationBenzinga
Aug-20-19 05:46PM Some TrovaGene (NASDAQ:TROV) Shareholders Have Copped A 99% Share Price Wipe OutSimply Wall St.
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)